MacroGenics Announces Positive Results from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer

World News: . []

ROCKVILLE MD May 15 2019 GLOBE NEWSWIRE -- MacroGenics Inc LINK  MGNX a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the LINK  of cancer today announ...

More news and information about MacroGenics, Inc.

Published By:

Globe Newswire: 22:07 GMT Wednesday 15th May 2019

Published: .

Search for other references to "macrogenics" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us